StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) stock

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)

Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –

Earnings

Puma Biotechnology's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$55.10M
+1.1% on a year earlier
Non-GAAP adjusted diluted net income per share, Q3 FY2026
$0.15
Latest guidance
Raised
Nov 5, 2026 · 10 items

Quarterly results

Revenue and earnings per share from each of Puma Biotechnology's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close$55.10M+1.1%$0.11$0.15Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026after the close$56.50M+7.8%$0.16$0.19Release
Q1 FY2026ended Mar 31, 2026May 7, 2026after the close$44.80M-2.6%-$0.07-$0.04Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026after the close$75.50M+27.7%$0.26$0.29Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025after the close$54.50M-32.3%––Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025after the close$52.40M+11.3%$0.12$0.15Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close$46.00M+5.0%$0.06$0.10Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025after the close$59.10M-18.1%$0.39$0.43Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close$80.50M+43.5%––Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024after the close$47.10M-13.7%-$0.09-$0.05Release
Q1 FY2024ended Mar 31, 2024May 2, 2024after the close$43.80M-17.0%-$0.10-$0.05Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Puma Biotechnology's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Net Product RevenueQ4 FY2026$56.00M – $58.00M–NewNov 5, 2026
Gross to Net AdjustmentQ4 FY202628% – 29%–NewNov 5, 2026
Net Income*Q4 FY2026$10.00M – $12.00M–NewNov 5, 2026
Net Product RevenueFY2026$206.00M – $208.00M–NewNov 5, 2026
Total RevenueFY2026$224.00M – $231.00M$0RaisedAug 6, 2026
Gross to Net AdjustmentFY202627.5% – 28%–NewNov 5, 2026
Gross to Net AdjustmentFY202626.5% – 27.5%27.5% – 28.5%LoweredAug 6, 2026
Net IncomeFY2026$17.00M – $20.00M–LoweredAug 6, 2026
Net Income*FY2026$20.00M – $22.00M–NewNov 5, 2026
Net Income/(Loss)*FY2026$10.00M – $13.00M–NewFeb 26, 2026
Net Product RevenueFY2026$205.00M – $209.00M–RaisedAug 6, 2026
Royalty RevenueFY2026$19.00M – $22.00M–LoweredAug 6, 2026

Guidance vs results

The last range Puma Biotechnology gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2026Revenue$56.00M – $59.00M$55.10MBelow range
Q2 FY2026Revenue$50.00M – $52.00M$56.50MAbove range
Q1 FY2026Revenue$36.00M – $39.00M$44.80MAbove range
Q3 FY2025Revenue$46.00M – $48.00M$54.50MAbove range
Q1 FY2025Revenue$41.00M – $43.00M$46.00MAbove range
Q3 FY2024Revenue$50.00M – $53.00M$80.50MAbove range
Q2 FY2024Revenue$43.00M – $45.00M$47.10MAbove range
Q1 FY2024Revenue$38.00M – $40.00M$43.80MAbove range
Q4 FY2023Revenue$56.00M – $59.00M$72.20MAbove range
Q3 FY2023Revenue$51.00M – $53.00M$56.10MAbove range
Q2 FY2023Revenue$47.00M – $50.00M$54.60MAbove range
Q1 FY2023Revenue$43.00M – $46.00M$52.80MAbove range

Guidance history

Every forecast Puma Biotechnology put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026Gross to Net AdjustmentQ4 FY202628% – 29%New
Nov 5, 2026Net Income*Q4 FY2026$10.00M – $12.00MNew
Nov 5, 2026Gross to Net AdjustmentFY202627.5% – 28%New
Nov 5, 2026Net Income*FY2026$20.00M – $22.00MNew
Nov 5, 2026Net Product RevenueQ4 FY2026$56.00M – $58.00MNew
Nov 5, 2026Royalty RevenueQ4 FY2026$11.00M – $12.00MLowered
Nov 5, 2026Total RevenueQ4 FY2026$67.00M – $70.00MRaised
Nov 5, 2026Net Product RevenueFY2026$206.00M – $208.00MNew
Nov 5, 2026Royalty RevenueFY2026$18.00M – $19.00MLowered
Nov 5, 2026Total RevenueFY2026$224.00M – $227.00MRaised
Aug 6, 2026Gross to Net AdjustmentFY202626.5% – 27.5%Lowered
Aug 6, 2026Net Product RevenueFY2026$205.00M – $209.00MRaised
Aug 6, 2026Royalty RevenueFY2026$19.00M – $22.00MLowered
Aug 6, 2026Net IncomeFY2026$17.00M – $20.00MLowered
Aug 6, 2026Gross to Net AdjustmentQ3 FY202626% – 27%New
Aug 6, 2026Net Product RevenueQ3 FY2026$54.00M – $56.00MNew
Aug 6, 2026Royalty RevenueQ3 FY2026$2.00M – $3.00MLowered
Aug 6, 2026Net IncomeQ3 FY2026$2.00M – $3.50MRaised
Aug 6, 2026Total RevenueFY2026$224.00M – $231.00MRaised
Aug 6, 2026Total RevenueQ3 FY2026$56.00M – $59.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Puma Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Update
  14. Results
  15. Results

See a number that looks wrong?